Mount Yale Investment Advisors LLC Has $2.55 Million Stake in Novartis AG (NYSE:NVS)

Mount Yale Investment Advisors LLC boosted its stake in shares of Novartis AG (NYSE:NVS) by 29.5% in the third quarter, Holdings Channel reports. The firm owned 22,167 shares of the company’s stock after acquiring an additional 5,052 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Novartis were worth $2,550,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gateway Investment Advisers LLC bought a new position in Novartis in the 1st quarter worth $230,000. Brookstone Capital Management lifted its position in shares of Novartis by 1.3% during the 1st quarter. Brookstone Capital Management now owns 12,833 shares of the company’s stock worth $1,241,000 after purchasing an additional 162 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Novartis by 5.2% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 111,453 shares of the company’s stock valued at $10,781,000 after purchasing an additional 5,491 shares during the period. Cypress Wealth Services LLC acquired a new stake in Novartis in the 1st quarter valued at approximately $202,000. Finally, Register Financial Advisors LLC bought a new position in Novartis in the 1st quarter worth approximately $56,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Down 0.8 %

Shares of NVS opened at $113.16 on Friday. Novartis AG has a 12 month low of $92.19 and a 12 month high of $120.92. The stock has a market cap of $231.30 billion, a price-to-earnings ratio of 15.27, a P/E/G ratio of 1.66 and a beta of 0.57. The company has a 50-day moving average price of $116.44 and a two-hundred day moving average price of $108.39. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on NVS shares. Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $135.00 to $130.00 in a research report on Wednesday, September 11th. Jefferies Financial Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $121.00 target price (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a research note on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $120.70.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.